Sangamo Therapeutics Inc (NASDAQ:SGMO) was the target of a large increase in short interest in the month of April. As of April 13th, there was short interest totalling 11,950,598 shares, an increase of 20.7% from the March 30th total of 9,901,110 shares. Based on an average daily trading volume, of 2,446,250 shares, the short-interest ratio is currently 4.9 days. Approximately 14.1% of the company’s shares are short sold.

In other news, VP Curt A. Herberts III sold 2,278 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $18.30, for a total value of $41,687.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven J. Mento sold 11,520 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.59, for a total transaction of $237,196.80. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $102,950. The disclosure for this sale can be found here. In the last three months, insiders sold 103,059 shares of company stock valued at $2,214,622. Corporate insiders own 5.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Fred Alger Management Inc. acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $148,000. Xact Kapitalforvaltning AB acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $175,000. Chicago Equity Partners LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $192,000. Great West Life Assurance Co. Can lifted its holdings in Sangamo Therapeutics by 150.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 7,667 shares in the last quarter. Finally, Jefferies Group LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $295,000. Institutional investors own 65.16% of the company’s stock.

Several equities analysts have recently commented on SGMO shares. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. Barclays restated a “buy” rating and issued a $30.00 price objective on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Piper Jaffray set a $25.00 price objective on shares of Sangamo Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Finally, Wedbush restated a “hold” rating and issued a $8.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sangamo Therapeutics currently has an average rating of “Buy” and a consensus price target of $20.83.

Shares of SGMO stock opened at $16.75 on Friday. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.13. Sangamo Therapeutics has a one year low of $4.25 and a one year high of $27.50. The company has a market capitalization of $1,507.62, a PE ratio of -23.93 and a beta of 2.80.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. During the same period in the prior year, the business posted ($0.14) EPS. The business’s revenue for the quarter was up 46.6% compared to the same quarter last year. equities analysts expect that Sangamo Therapeutics will post -0.15 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.